Trimipramine Maleate

Indications and usage: Trimipramine Maleate Capsules are indicated for the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. In studies with neurotic outpatients, the drug appeared to be equivalent to amitriptyline in the less-depressed patients but somewhat less effective than amitriptyline in the more severely depressed patients. In hospitalized depressed patients, trimipramine and imipramine were equally effective in relieving depression.

CLINICAL PHARMACOLOGY Trimipramine maleate is an antidepressant with an anxiety-reducing sedative component to its action. The mode of action of trimipramine maleate on the central nervous system is not known. However, unlike amphetamine-type compounds it does not act primarily by stimulation of the central nervous system. It does not act by inhibition of the monoamine oxidase system. The single-dose pharmacokinetics of trimipramine were evaluated in a comparative study of 24 elderly subjects and 24 younger subjects; no clinically relevant differences were demonstrated based on age or gender.

Clinical clearance of Trimipramine Maleate (Tricyclic Antidepressant) relies on mixed metabolic conjugation and unchanged urinary excretion across trimipramine maleate regimens with a Terminal t½ estimated at 10–19 hrs depending on renal/hepatic reserve (Trimipramine Maleate) half-life; patients absorbing at F ≈ 79%–91% systemic availability after standard oral Trimipramine Maleate administration bioavailability typically observe target onset around time to peak concentration spans 1 to 4 hrs under trimipramine maleate maintenance.

FDA clinical labeling for Trimipramine Maleate restricts administration in severe drug-induced hypersensitivity to trimipramine maleate or inactive tablet/vehicle binders; prohibited co-prescriptions or physiological states specified in fda spl 2023-06-14 for trimipramine maleate across 25 mg/1 Capsule, 100 mg/1 Capsule, 50 mg/1 Capsule, 100mg Capsule, 25mg Capsule, with self-reported patient tracking dominated by nausea (9.2% of reports), headache (7.4% of reports), insomnia (6.7% of reports).